Dyne Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+2.51%
vs ±16.7% implied · ×0.15
shaded = implied · ▲▼ = realized
No thesis.
Dyne Therapeutics, Inc.
18.55
pre 18.00 −2.91%
Fund move
Fund move
News
Largest filed tie
—
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | T. Rowe Price Investment ManagementT. Rowe Price | $686.6M | 16.21% | +0.41% | |
| 2 | BlackRockBlackRockindex-like | $275.5M | 6.50% | +6.02% | |
| 3 | Jupiter TopcoJupiter Topco | $266.6M | 6.29% | — | |
| 4 | FMRFMR | $248.9M | 5.88% | +25.79% | |
| 5 | State StreetState Streetindex-like | $165.6M | 3.91% | +12.09% | |
| 6 | Orbis Allan GrayOrbis Allan Gray | $155.6M | 3.67% | +3.61% | |
| 7 | Atlas Venture Life Science AdvisorsAtlas Venture Life Science | $151.0M | 3.57% | −25.52% | |
| 8 | Vanguard Capital ManagementVanguardindex-like | $140.2M | 3.31% | −1.47% | |
| 9 | TCG Crossover ManagementTCG Crossover | $102.5M | 2.42% | 0.00% | |
| 10 | Vanguard Portfolio ManagementVanguard Portfolioindex-like | $89.9M | 2.12% | −2.73% | |
| 11 | T. Rowe Price AssociatesT. Rowe Price | $87.4M | 2.06% | +69.08% | |
| 12 | Fcpm III Services B.V.Fcpm III Services B.V. | $85.5M | 2.02% | −17.14% | |
| 13 | Geode Capital ManagementGeodeindex-like | $83.2M | 1.96% | +6.83% | |
| 14 | Vestal Point CapitalVestal Point Capital | $75.0M | 1.77% | −15.63% | |
| 15 | Orbimed AdvisorsOrbimed | $71.9M | 1.70% | +10.89% | |
| 16 | Frazier Life Sciences ManagementFrazier Life Sciences | $70.0M | 1.65% | 0.00% | |
| 17 | Armistice CapitalArmistice Capital | $68.6M | 1.62% | −2.77% | |
| 18 | JPMorgan ChaseJPMorgan Chase | $67.2M | 1.59% | new | |
| 19 | Perceptive AdvisorsPerceptive | $59.7M | 1.41% | −42.40% | |
| 20 | Logos Global ManagementLogos Global | $56.6M | 1.34% | +82.14% | |
| 21 | Bank of AmericaBank of America | $49.6M | 1.17% | +54.74% | |
| 22 | VR AdviserVR Adviser | $48.3M | 1.14% | 0.00% | |
| 23 | Goldman Sachs GroupGoldman Sachs | $47.9M | 1.13% | +25.19% | |
| 24 | SirenSiren | $47.3M | 1.12% | −4.49% | |
| 25 | Franklin ResourcesFranklin Resources | $45.1M | 1.06% | +1.08% |
245 managers report $4.2B of Dyne Therapeutics on form 13F for the quarter ended Jun 30 '26. 29 of them hold 80% of it; T. Rowe Price is largest at 16.21%.
Expected move
No implied move.
No implied move.
No implied move.